This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Herbst, R. S. Articles by Lahn, M. Search for Related Content PubMed PubMed Citation Articles by Herbst, R. S. Articles by Lahn, M.

Enzastaurin, a Protein Kinase Cß–Selective Inhibitor, and Its Potential Application as an Anticancer Agent in Lung Cancer

Authors' Affiliations: ¹ M. D. Anderson Cancer Center, Houston, Texas and ² Eli Lilly and Company, Indianapolis, Indiana

Requests for reprints: Roy S. Herbst, M. D. Anderson Cancer Center, University of Texas, 1515 Holcombe Boulevard, Box 80, Houston, TX 77030-4009. Phone: 713-792-6363; Fax: 713-796-8655; E-mail: rherbst{at}mdanderson.org.

Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through protein kinase C (PKC)-ß and the phosphatidylinositol 3-kinase/AKT pathway to induce tumor cell apoptosis, reduce proliferation, and suppress tumor-induced angiogenesis. In contrast to previous PKC inhibitors, enzastaurin is very well tolerated with a favorable safety profile, allowing it to be dosed for extended durations. In the present review, we summarize the rationale for targeting PKC in cancer, the preclinical experience of enzastaurin, and the clinical findings of the current phase I and II studies. Based on the combined information, we present the rationale for its future assessment in the treatment of lung cancer.

This article has been cited by other articles:

				M. Zemskova, E. Sahakian, S. Bashkirova, and M. Lilly The PIM1 Kinase Is a Critical Component of a Survival Pathway Activated by Docetaxel and Promotes Survival of Docetaxel-treated Prostate Cancer Cells J. Biol. Chem., July 25, 2008; 283(30): 20635 - 20644. [Abstract] [Full Text] [PDF]